CTH announces fiscal 1995 results.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 29, 1995--Cancer Treatment Holdings, Inc. (AMX/ECM: CTH.EC) today announced financial results for the fiscal year ended May 31, 1995.

Revenues increased to $11,017,000 in fiscal 1995 from $7,519,000 in fiscal 1994. The Company reported net income of $514,000, or $.15 per share, for 1995 as compared to a net loss of $297,000, or $.09 per share, for fiscal 1994.

The Company also announced the following events:

The Company has formed a medical/scientific advisory board consisting of five experts in oncology and bone marrow transplants and expects to open its first wholly-owned bone marrow/stem cell transplantation center within 90 days.

In order to comply with the self-referral restrictions contained in the "Stark I" and "Stark II" regulations, the Company has sold its minority interest in two radiation therapy centers located in Tampa, Florida (21%), and Macon, Georgia (9%). As a result of the sales, the Company received approximately $550,000 in cash and a 10-year consulting agreement under which the Company will receive $150,000 per year. The Company will continue in its billing and collection agreement at the Macon center. At the center in West Palm Beach, the Company and Intercoastal Health Systems ("IHS"), the parent corporation of Good Samaritan Hospital, have jointly bought out the referring physicians, so that IHS and the Company each now own 50% of the center.

In addition, the Company has been awarded a certificate of need to provide home health services to Medicare patients in the counties of Palm Beach, Martin and St. Lucie, Florida. The Company expects to begin providing these services by January 1, 1996.

Finally, Stanley Malkin, M.D., has resigned as president of the Company although he will continue to serve as Senior Medical Director. Ullrich Klamm, Ph.D., the Company's chairman and CEO, has been elected president of the Company.

CTH is engaged in the ambulatory treatment of cancer using a variety of modalities including radiation therapy, home infusion and home health care. -0-

    The following table summarizes selected financial data of the
Company:

                                     Year ended May 31
                                  1995              1994
OPERATING DATA
Revenues                       $11,016,839        $7,519,096
Net income (loss)              $   514,054        $(297,438)
Net income (loss) per share    $       .15        $    (.09)

BALANCE SHEET DATA              May 31, 1995
Current assets                   $4,592,854
Current liabilities              $2,023,641
Working capital                  $2,569,213
Current ratio                          2.27

Total assets                     $8,694,845
Long-term debt                   $  180,085

    Average common shares outstanding  3,495,765

CONTACT: Cancer Treatment Holdings, Inc.

Ullrich Klamm, 305/321-9555